NCT00920088View on ClinicalTrials.gov

Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Healthy SubjectsInfection, Human Immunodeficiency Virus
Interventions
DRUG

darunavir/ritonavir

DRV/RTV 600/100mg

DRUG

lopinavir/ritonavir

LPV/RTV 400/100mg

DRUG

Midazolam

Midazolam 3mg

DRUG

Dextromethorphan

Dextromethorphan 30mg

DRUG

Flurbiprofen

Flurbiprofen 50mg

DRUG

GSK2248761

NNRTI under investigation

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00920088 - Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs | Biotech Hunter | Biotech Hunter